scholarly journals Eradication of hepatitis C virus preserve liver function and prolong survival in advanced hepatocellular carcinoma patients with limited life expectancy

2020 ◽  
Author(s):  
Ming‐Lun Yeh ◽  
Hsing‐Tao Kuo ◽  
Ching‐I Huang ◽  
Chung‐Feng Huang ◽  
Ming‐Yen Hsieh ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Life Expectancy ◽  
Liver Function ◽  
Advanced Hepatocellular Carcinoma ◽  
Limited Life Expectancy ◽  
Preserve Liver Function ◽  
Limited Life

scholarly journals Epidemiological Characteristics of Advanced Hepatocellular Carcinoma in the Northern Region of Vietnam

2019 ◽  
Vol 26 (1) ◽  
pp. 107327481986279 ◽  
Author(s):  
Van Quang Le ◽  
Van Hieu Nguyen ◽  
Van Hung Nguyen ◽  
Thanh Long Nguyen ◽  
Staci L. Sudenga ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Hcv Infection ◽  
High Rate ◽  
Advanced Hepatocellular Carcinoma ◽  
Female Ratio ◽  
Advanced Hcc ◽  
Significant Difference ◽  
Epidemiological Characteristics

Epidemiological characteristics of hepatocellular carcinoma (HCC) in Southern Vietnam has been well reported as in Globocan 2018 while data from the North has still not been fully presented. Therefore, we conducted this retrospective descriptive study on 198 advanced HCC patients treated at 3 major hospitals in Northern Vietnam to describe demographic features, HCC risk factors, and correlation among them in patients with advanced HCC. This information will lead to prevention efforts and provide information for allocating funds for treatment. The median age at diagnosis was 57 years (range: 19-86) and the male/female ratio was 8.9/1. The proportions of hepatitis B virus (HBV) and hepatitis C virus (HCV) infection were 81.3% and 5.6%, respectively. Hepatitis C virus infection rate was significantly higher in patients <50 years old (12.5% vs 3.3%, P = .016). There was no significant difference in age or viral hepatitis infection status by gender. Only 7.6% of patients diagnosed with advanced HCC were asymptomatic. In conclusion, with the high rate of HBV infection among patients with advanced HCC, it is necessary for increasing prevention efforts in HBV screening. Furthermore, HCV infection should be noticed in patients with advanced HCC younger than 50 years old.

scholarly journals A case of advanced hepatocellular carcinoma with hepatitis C virus infection treated effectively with Peg-IFNα2a

Kanzo ◽  
2015 ◽  
Vol 56 (6) ◽  
pp. 280-288
Author(s):  
Takayuki Iwamoto ◽  
Kazuto Fukuda ◽  
Yoshiyuki Sawai ◽  
Sachiyo Kogita ◽  
Takumi Igura ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Virus Infection ◽  
Advanced Hepatocellular Carcinoma ◽  
Hepatitis C Virus Infection

scholarly journals Characteristics and Survival Outcomes of Hepatocellular Carcinoma Developed after HCV SVR

Cancers ◽  
2021 ◽  
Vol 13 (14) ◽  
pp. 3455
Author(s):  
Ming-Lun Yeh ◽  
Po-Cheng Liang ◽  
Pei-Chien Tsai ◽  
Shu-Chi Wang ◽  
Jennifer Leong ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Overall Survival ◽  
Multivariate Analysis ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Propensity Score ◽  
Liver Function ◽  
Median Survival ◽  
Clinical Presentation ◽  
Survival Outcomes

The clinical presentation and survival of hepatocellular carcinoma (HCC) after hepatitis C virus (HCV) eradication as compared to HCC in viremic patients are not well characterized. We aimed to investigate the characteristics and survival between HCV patients with and without viremia at HCC diagnosis.: We retrospectively analyzed overall survival outcomes in 1389 HCV-related HCC patients, including 301 with HCC developed after HCV eradication (post-SVR HCC) and 1088 with HCV viremia at HCC diagnosis (viremic HCC). We also evaluated overall survival in the two groups using propensity score-matching methods.: At HCC diagnosis, post-SVR HCC patients were older, less obese, less likely cirrhotic, with better liver function, lower alfa-fetoprotein levels, earlier BCLC stages, and higher rate of treatment with surgery. Overall, post-SVR HCC patients had higher median survival than viremic patients (153.3 vs. 55.6 months, p < 0.01), but post-SVR HCC was not independently associated with survival on multivariate analysis (adjusted HR: 1.05, 95% CI: 0.76–1.47). However, on sub-analysis, viremic HCC patients who subsequently received anti-viral treatment and achieved SVR had higher median survival than post-SVR HCC patients (p < 0.01). Viremic HCC with subsequent SVR was also significantly associated with lower mortality as compared to post-SVR HCC (adjusted HR: 0.18, 95% CI: 0.11–0.29). In addition, we observed similar findings in our analysis of the propensity score-matched cohorts.: The advantages in clinical and tumor characters at HCC diagnosis determined the better overall survival of post-SVR HCC patients; however, HCV eradication after HCC development was also associated with improved survival.

Natural history of advanced hepatocellular carcinoma in Crete. Association with hepatitis C virus

1997 ◽  
Vol 9 (10) ◽  
pp. 981-988 ◽  
Author(s):  
Elias A. Kouroumalis ◽  
Panagiotis G. Skordilis ◽  
Joanna Moschandrea ◽  
Georgios Alexandrakis ◽  
Nikolaos Charoulakis ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Natural History ◽  
Advanced Hepatocellular Carcinoma ◽  
History Of

scholarly journals Phase II Study of Personalized Peptide Vaccination with Both a Hepatitis C Virus-Derived Peptide and Peptides from Tumor-Associated Antigens for the Treatment of HCV-Positive Advanced Hepatocellular Carcinoma Patients

2015 ◽  
Vol 2015 ◽  
pp. 1-8 ◽  
Author(s):  
Shigeru Yutani ◽  
Kazuomi Ueshima ◽  
Kazumichi Abe ◽  
Atsushi Ishiguro ◽  
Junichi Eguchi ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Core Protein ◽  
Cytotoxic T Lymphocyte ◽  
Subcutaneous Administration ◽  
Advanced Hepatocellular Carcinoma ◽  
Peptide Vaccination ◽  
Advanced Hcc ◽  
Tumor Associated Antigens

Objective. To evaluate safety and immune responses of personalized peptide vaccination (PPV) for hepatitis C virus- (HCV-) positive advanced hepatocellular carcinoma (HCC).Patients and Methods. Patients diagnosed with HCV-positive advanced HCC were eligible for this study. A maximum of four HLA-matched peptides were selected based on the preexisting IgG responses specific to 32 different peptides, which consisted of a single HCV-derived peptide at core protein positions 35–44 (C-35) and 31 peptides derived from 15 different tumor-associated antigens (TAAs), followed by subcutaneous administration once per week for 8 weeks. Peptide-specific cytotoxic T lymphocyte (CTL) and IgG responses were measured before and after vaccination.Results. Forty-two patients were enrolled. Grade 3 injection site skin reaction was observed in 2 patients, but no other PPV-related severe adverse events were noted. Peptide-specific CTL responses before vaccination were observed in only 3 of 42 patients, but they became detectable in 23 of 36 patients tested after vaccination. Peptide-specific IgG responses were also boosted in 19 of 36 patients. Peptide-specific IgG1 responses to both C-35 and TAA-derived peptides could be potentially prognostic for overall survival.Conclusion. Further clinical study of PPV would be warranted for HCV-positive advanced HCC, based on the safety and strong immune induction.

To treat or not to treat – Successful hepatitis C virus eradication in a patient with advanced hepatocellular carcinoma and complete response to sorafenib

2016 ◽  
Vol 55 (06) ◽  
pp. 564-568 ◽  
Author(s):  
Oliver Waidmann ◽  
Jan Peveling-Oberhag ◽  
Katrin Eichler ◽  
Falko Schulze ◽  
Johannes Vermehren
Keyword(s):  
Hepatocellular Carcinoma ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Antiviral Treatment ◽  
Objective Response ◽  
Local Treatment ◽  
Complete Response ◽  
Advanced Hepatocellular Carcinoma ◽  
Current Guideline ◽  
Sorafenib Treatment

Abstract Background and aims Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related death worldwide. Infection with the hepatitis C virus (HCV) is one of the most frequent underlying diseases leading to HCC development. Sorafenib is the standard of care for HCC patients not amenable to local treatment, resection, or liver transplantation. Although overall survival can be increased, objective response rates in patients treated with sorafenib are low. In HCC patients who underwent resection or ablation, HCV eradication with interferon-based regimens reduces the risk of recurrence. However, it is not known and under strong debate if patients with HCC should be treated with interferon-free regimens. Furthermore, it is not known if patients with advanced HCC at the time of diagnosis should be treated with antiviral therapy. Methods A patient with histologically confirmed advanced-stage HCC due to HCV-related cirrhosis was treated with sorafenib according to current guideline recommendations. Furthermore, he received subsequent treatment with direct antiviral agents (DAAs). Results The patient achieved a complete response after sorafenib treatment was initiated. Sorafenib treatment was terminated 1 year after complete response. As no recurrence of HCC was evident after treatment cessation, antiviral treatment was initiated with paritaprevir/ritonavir, ombitasvir, dasabuvir, and dose-reduced ribavirin because of chronic kidney disease. The patient achieved a sustained viral response. Conclusions Complete response to sorafenib treatment is scarce. Antiviral treatment should be considered in such patients as well as in patients with HCC who underwent resection or ablation.

Disparities in Time to Treatment of Hepatocellular Carcinoma in Patients with Hepatitis B Virus versus Hepatitis C Virus

2017 ◽  
Vol 05 (03) ◽  
Author(s):  
Jennifer Wu ◽  
Tsivia Hochman ◽  
Judith D Goldberg ◽  
Jafar Al Mondhiry ◽  
Bennal Perkins ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Time To Treatment ◽  
B Virus ◽  
Virus Versus
Sign in / Sign up

Export Citation Format

Share Document